Maksal Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 03-12-2024
- Paid Up Capital ₹ 3.00 M
as on 03-12-2024
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
About Maksal Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 3.00 M, as per Ministry of Corporate Affairs (MCA) records.
Anjul Bansal, Kamlesh Bansal, and Dhananjaya Bansal serve as directors at the Company.
- CIN/LLPIN
U36900DL2017PTC314079
- Company No.
314079
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Mar 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Maksal Pharmaceuticals Private Limited offer?
Maksal Pharmaceuticals Private Limited offers a wide range of products and services, including Construction Service, Residential Construction Projects, Building & Real Estate Developers, Building Construction, Real Estate Services.
Who are the key members and board of directors at Maksal Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dhananjaya Bansal  | Director | 07-Mar-2017 | Current |
| Anjul Bansal | Director | 07-Mar-2017 | Current |
| Kamlesh Bansal | Director | 07-Mar-2017 | Current |
Financial Performance and Corporate Structure Insights of Maksal Pharmaceuticals.
Maksal Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Maksal Pharmaceuticals?
In 2017, Maksal Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vrinda Urban Projects Private LimitedActive 15 years 5 monthsAnjul Bansal and Kamlesh Bansal are mutual person
- Raghunandan Infra Projects Private LimitedActive 20 years 4 days
Anjul Bansal and Kamlesh Bansal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Maksal Pharmaceuticals?
Unlock and access historical data on people associated with Maksal Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Maksal Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Maksal Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
